• Gómez GarcíaTeresaTServicio de Neumología, Hospital General Universitario Gregorio Marañón, Universidad Complutense, Madrid, España., Javier de Miguel Díez, and Adolfo Baloira Villar.
• Servicio de Neumología, Hospital General Universitario Gregorio Marañón, Universidad Complutense, Madrid, España.
• Arch. Bronconeumol. 2011 Jan 1; 47 Suppl 1: 7-11.

AbstractIn both thromboembolic disease and pulmonary hypertension, 2010 has been a prodigious year for interesting publications. Some data have helped to elucidate the factors associated with a greater risk of thromboembolic disease, such as long journeys and certain polymorphisms. New recommendations on diagnosis have been made, giving a greater role to computed tomography angiography. Magnetic resonance imaging is also gaining ground. More accurate risk evaluation is one of the objectives of the new guidelines of the European Society of Cardiology, which substitute some terms such as massive or submassive for high- and low-risk. Maintaining anticoagulation indefinitely in idiopathic pulmonary thromboembolism is recommended. Evidence on the efficacy of new drugs such as rivaroxaban, dabigatran and indraparinux is beginning to appear. In pulmonary hypertension, smoking seems to play a role as a risk factor. Some registries indicate that new treatments have not improved survival. Greater knowledge has been gained of the role of inflammation in the pathogenesis of the disease and a Spanish study supports the role of the 6-minute walk test in patient evaluation. Some drugs are highlighted in the literature. Imatinib is promising but probably only in some patients. Riociguat provides good results and inhaled treprostinil has emerged as a new option.Copyright © 2011 Sociedad Española de Neumología y Cirugía Torácica. Published by Elsevier Espana. All rights reserved.

19 keywords...

hide…